ALFA Finder| Revenue growth | 28% YoY growth to ₹411cr; 9M revenue up 14%. |
|---|---|
| Margins | EBITDA margins healthy at 28% due to positive operating leverage. |
| Order book | Firm orders for Nor-UDCA in Q4; CDMO pipeline expanding. |
| Demand visibility | Strong visibility for specialty CDMO and EU formulation exports. |
| Management confidence | High; focusing on execution and asset monetization after heavy capex. |
Growth
Revenue grew 28% YoY to ₹411cr, driven by a 100% surge in formulation exports to the EU.
Outlook
Guidance suggests a steady 150cr annual licensing run rate and ROIC improvement to 17% in 9MFY26.
Risks
Regulatory dependency on USFDA for the Jadcherla facility and high net debt of ₹625cr remain key concerns.
Earnings Call filed with BSE, NSE: SHILPAMED. Summary written with AI assistance from the document.
Shilpa Medicare Ltd: key numbers
- Share price
- ₹991.50
- Market cap
- ₹19,392 Cr
- Revenue (annual)
- ₹1,539 Cr
- Net profit (annual)
- ₹243.3 Cr
- P/E (TTM)
- 58.3×Sector 43.7×
- Promoter holding
- 40.13%+0.00% QoQ
- FII holding
- 12.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shilpa Medicare Ltd
All →Shilpa Medicare Earnings Call Transcript: Key Takeaways
Record Q2 revenue of ₹538 Cr (+35%) and EBITDA of ₹151 Cr (28% margin), but gross margin fell roughly 700 bps and management deflected several key questions.
Shilpa Medicare Insolvency Petition
Shilpa Medicare reports NCLAT set aside the CIRP against its subsidiary FTF Pharma, annulling the process. The filing states no impact on the listed entity.
Shilpa Medicare Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 538 cr (+45% YoY), EBITDA INR 151 cr (28% margin), PAT INR 79 cr (+80%). 1HFY27 total income INR 1,007 cr (+44%). Strategy: complex FDF launches, CDMO, biologics, rHA.
Shilpa Medicare Q2 FY27 Results: Net Profit ₹79.2 Cr, Up 79.6% YoY
Shilpa Medicare Ltd reported revenue from operations of ₹529.1 Cr (+43.0% YoY) and net profit of ₹79.2 Cr (+79.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹79.2 Cr · +79.6% YoY
Shilpa Medicare Board Meeting Date
Shilpa Medicare's board meeting is scheduled for 5 November 2026 to approve Q2 and H1 unaudited financial results. The trading window remains closed until 7 November 2026.
Shilpa Medicare Business Update
Shilpa Medicare Limited’s Unit 4 in Jadcherla received GMP certification from AGES, Austria, following a successful inspection. This milestone enables operations for European and global markets.